Q3 2025 Imunon Inc Earnings Call Transcript

Nov 13, 2025 / 04:00 PM GMT

Release Date Price: $11.48

Transcript 10-Q8-K

Key Points

Positve

Imunon Inc (IMNN) is making significant progress with its IL-12 immunotherapy, Immunon 001, particularly in the Ovation 3 pivotal phase 3 trial for advanced ovarian cancer.
The Ovation 2 study demonstrated the first-ever overall survival benefit in a critical FDA endpoint, indicating strong potential for Immunon 001.
Enrollment for the Ovation 3 trial is ahead of schedule, with strong investigator enthusiasm and a robust start to the trial.
The company has successfully managed its cash flow, reducing operating expenses by 31% year-over-year, which includes a 44% decrease in R&D expenses.
Imunon Inc (IMNN) has achieved compliance with NASDAQ's $1 minimum bid price requirement and maintains a strong shareholder equity position.

Negative

The company faces a challenging biotech capital markets environment, which could impact its ability to secure necessary funding.
Imunon Inc (IMNN) is currently constrained by its cash position, which limits the speed at which it can conduct its trials.
The company has not yet secured any imminent partnerships, which are crucial for non-dilutive funding.
There is uncertainty regarding the timeline for full enrollment in the Ovation 3 trial, which is estimated to be completed by late 2028.
The financial outlook is dependent on successful interim analyses and potential partnerships, which are not guaranteed.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMNN.OQ - Imunon Inc
Q3 2025 Imunon Inc Earnings Call
Nov 13, 2025 / 04:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Myron Fernandez, and I will be your operator today.

At this time I would like to welcome you all to imminent 3rd quarter financial results conference call.

All lines have been placed on mute to prevent any background noise.

Following the speaker's prepared remarks, there'll be a question-and-answer session.

You may press star and one on your phone to ask a question at that time.

Please keep in mind if you're using a speakerphone, you must release your mute function to allow the signal to reach our equipment.

Again, that's star and one to ask a question during the QA session.

I would now like to turn the call over to Peter Wozzo from ICR Healthcare Investor

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.